A novel cytotoxic anti-B7-H3 affibody with therapeutic potential in acute myeloid leukemia
In conclusion, we designed, produced and evaluated a novel anti-B7-H3 cytotoxic affibody-drug conjugate (AfDC) that, from these preliminary <i>in vitro</i> data, shows high potential for translation to the therapy of AML, warranting further preclinical and translational exploration, including pharmacokinetic and <i>in vivo</i> efficacy studies.
Authors
- Ștefan-Eugen Szedlacsek
- Adina-Gabriela Vasilescu
- Natalia Baran (ORCID: https://orcid.org/0000-0003-0618-4798)
- Cristian V. A. Munteanu (ORCID: https://orcid.org/0000-0002-2998-0458)
- Livia Elena Sima (ORCID: https://orcid.org/0000-0002-3404-4162)
- Andrei-Mihai Vasilescu
Institutions
- University of Bern (CH)
- University of Sioux Falls (US)
- University Hospital of Bern (CH)
- Academia Oamenilor de Știință din România (RO)
- Institute of Biochemistry (RO)
- Romanian Academy (RO)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3389/fphar.2025.1684226
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00